Invention Grant
- Patent Title: siRNA compounds for inhibiting NRF2
- Patent Title (中): 用于抑制NRF2的siRNA化合物
-
Application No.: US12988307Application Date: 2009-04-06
-
Publication No.: US08278287B2Publication Date: 2012-10-02
- Inventor: Elena Feinstein , Igor Mett , Hagar Kalinski
- Applicant: Elena Feinstein , Igor Mett , Hagar Kalinski
- Applicant Address: US CA Fremont
- Assignee: Quark Pharmaceuticals Inc.
- Current Assignee: Quark Pharmaceuticals Inc.
- Current Assignee Address: US CA Fremont
- Agency: Cooper & Dunham LLP
- Agent John P. White
- International Application: PCT/IL2009/000387 WO 20090406
- International Announcement: WO2009/144704 WO 20091203
- Main IPC: A61K31/70
- IPC: A61K31/70 ; C07H21/02 ; C07H21/04
Abstract:
The present invention provides chemically modified siRNA compounds that target the Nrf2 gene and pharmaceutical compositions comprising same useful for treating or preventing the incidence or severity of a cancerous disease, particularly various lung cancers.
Public/Granted literature
- US20110105591A1 siRNA COMPOUNDS FOR INHIBITING NRF2 Public/Granted day:2011-05-05
Information query
